Author(s): ,
Rainer Boxhammer
MorphoSys AG,Martinsried/Planegg,Germany
Stefan Steidl
MorphoSys AG,Martinsried/Planegg,Germany
Jan Endell
MorphoSys AG,Martinsried/Planegg,Germany
EHA Learning Center. Boxhammer R. Jun 13, 2015; 100777
Disclosure(s): MorphoSys AG
Rainer Boxhammer
Rainer Boxhammer

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.

Discussion Forum (0)
Rate & Comment (0)
Abstract: P636

Type: Poster Presentation

Presentation during EHA20: From 13.06.2015 17:15 to 13.06.2015 18:45

Location: Poster area (Hall C)

MOR202 (MOR03087), a human CD38 antibody currently under evaluation in a phase I/IIa trial, mediates antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/ADCP) of multiple myeloma patient-derived cells with high potency (EC50 ~200 pM). 

To evaluate in vitro the ability of the IMiD compounds lenalidomide and pomalidomide, both of which are approved for multiple myeloma, to modulate CD38 expression and enhance the cytotoxicity of MOR202.

CD38 expression +/- lenalidomide and +/- pomalidomide on multiple myeloma cell lines was analyzed by flow cytometry. The antitumor activity of pomalidomide combined with MOR202 was evaluated in vitro; analyses included the induction of direct cytotoxicity on multiple myeloma cells and the activation of immune effector cells. On a functional level, the combinatorial effects of MOR202 with pomalidomide were assessed in ADCC assays. Different incubation schemes were used to separate the effect of pomalidomide on target and effector cells, as well as in the evaluation of the combined effects. The observed combination effects were analyzed for synergistic potential using the fractional product concept.

Pomalidomide and lenalidomide mediated a substantial CD38 upregulation on multiple myeloma cell lines. Pomalidomide as a single agent demonstrated activation of effector cells with high potency (EC50 ~150 nM), and demonstrated cytotoxic effects on multiple myeloma cell lines. Additionally, pomalidomide dose-dependently induced an up to 3-fold CD38 upregulation (EC50 ~20 nM) on CD38-expressing multiple myeloma cell lines. Pomalidomide-mediated effects were time-dependent, with the most pronounced effects after 72 h incubation. Combining MOR202 with pomalidomide led to a synergistic enhancement of cytotoxic activity. The synergic benefit ranged 1.2–3.1-fold above theoretical additivity depending on the cell line used, and was most prominent in the case of strong CD38 upregulation.

Upregulation of CD38 was mediated by both lenalidomide and pomalidomide and may represent a class effect of IMiD compounds. The cytotoxic activity of MOR202 on multiple myeloma cells was enhanced by pomalidomide via multiple mechanisms: direct cytotoxicity, CD38 upregulation and activation of effector cells. These results provide a mechanistic rationale for the combination of MOR202 with IMiD compounds and warrant further clinical evaluation.

Keyword(s): ADCC, Antibody, CD38 expression, Multiple myeloma

Session topic: Multiple myeloma - Biology 2
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings